SEC Form 4 · accession 0001104659-18-047776
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven P. Gelone
Officer — President and COO
Period of report
Jul 25, 2018
Accepted (ET)
Jul 27, 2018 · 5:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | Jul 25, 2018 | A | 77,500 | A | — | Jul 25, 2028 | Ordinary Shares | 77,500 | 77,500 | D |
Explanation of responses
- F1The exercise price is $3.53 per share.
- F2The option award was granted on July 25, 2018. Vesting began on July 24, 2018 and ends on July 24, 2022. Twenty-five percent (25%) of the option award will vest on July 24, 2019, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.